INVO Fertility, Inc. is a healthcare services company focused on the fertility marketplace and dedicated to expanding access to assisted reproductive technology care to patients in need. The company builds acquires and operates fertility clinics including INVO Centers that offer the intravaginal culture procedure using its INVOcell device and also owns and operates a traditional in vitro fertilization clinic.

The company generates revenue primarily from patient fees for fertility clinic services such as in vitro fertilization intrauterine insemination and intravaginal culture procedures. It also earns income from the sale of its INVOcell medical device to third party fertility clinics that wish to offer the intravaginal culture treatment. Additional future revenue may arise from partnerships related to its bispecific antibody therapeutics.

The company operates through the following segments: Fertility Clinics, INVOcell Device, and NAYA Therapeutics.

• The Fertility Clinics segment operates two INVO Centers in Alabama and Georgia through joint ventures and owns the Wisconsin Fertility Institute providing in vitro fertilization intrauterine insemination and intravaginal culture services to patients.

• The INVOcell Device segment designs manufactures and sells the INVOcell medical device which enables the intravaginal culture procedure for fertilization and early embryo development within the womb.

• The NAYA Therapeutics segment focuses on the development of bispecific antibody therapeutics for oncology and autoimmune diseases with candidates targeting hepatocellular carcinoma and multiple myeloma.

Within the fertility industry INVO Fertility occupies a niche by offering a lower cost intravaginal culture alternative that delivers pregnancy success rates comparable to traditional in vitro fertilization while providing a more natural patient experience. The company competes with established IVF clinics and other assisted reproductive technology providers but differentiates itself through reduced laboratory requirements and competitive pricing. In the biotechnology arena NAYA Therapeutics positions itself among emerging bispecific antibody developers with novel mechanisms that aim to improve efficacy and safety over existing monoclonal antibody therapies.

The company serves individual patients seeking fertility treatment, fertility clinics that purchase its INVOcell device, and OBGYN practices that refer patients for assisted reproductive services. Specific customer names are not disclosed in the filing.